Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25530468 | 0.93 | TSHR (0.48) | TSHRBBOX1LMNAKDM4EALDH1A1 | |
| SCHEMBL25541415 | 0.83 | TSHR (0.38) | TSHRBBOX1LMNAKDM4EALDH1A1 | |
| SCHEMBL16417786 | 0.81 | BBOX1 (0.63) | TSHRBBOX1LMNAKDM4EALDH1A1 | |
| SCHEMBL15876373 | 0.80 | BBOX1 (0.59) | TSHRBBOX1LMNAALDH1A1MEN1 | |
| SCHEMBL23016767 | 0.79 | HTT (0.56) | TSHRLMNAKMT2ACA12CA14 | |
| Bromide SCHEMBL13731886 | 0.79 | BBOX1 (0.61) | TSHRBBOX1LMNAALDH1A1MEN1 | |
| SCHEMBL25530704 | 0.79 | TSHR (0.39) | TSHRLMNAKDM4EALDH1A1MEN1 | |
| SCHEMBL16417788 | 0.78 | TSHR (0.54) | TSHRBBOX1LMNAKDM4EALDH1A1 | |
| Bromide SCHEMBL1672731 | 0.78 | BBOX1 (0.57) | TSHRBBOX1LMNAALDH1A1MEN1 | |
| Carpronium SCHEMBL195274 | 0.77 | TSHR (0.64) | TSHRLMNAKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | TSHR 948/4885BBOX1 3187/4885LMNA 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.